Premature Ovarian Failure and Fertility in Long-Term Survivors of Hodgkin's Lymphoma: A European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study

Autor: Berthe M.P. Aleman, Natacha Heutte, Jeanette K. Doorduijn, Elizabeth C. Moser, Hanneke C. Kluin-Nelemans, Pieternella J. Lugtenburg, Isabelle Gaillard, Serge Bologna, Michel Henry-Amar, Houchingue Eghbali, Franck Morschhauser, Marleen A. E. van der Kaaij, Arnold Simons, Catherine Sebban, Pauline Brice, Bart Meulemans, Marie Bouteloup, Christophe Fruchart, Paul Meijnders, Judith M. Roesink, John M. M. Raemaekers, Achiel Van Hoof, Christophe Fermé, Francisca Ong, José Thomas, Michele Spina, Anouk Allgeier, Aspasia Stamatoullas, Edwige Abeilard-Lemoisson, Evert M. Noordijk
Přispěvatelé: Centre d’études des transformations des activités physiques et sportives (CETAPS), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut de Recherche Interdisciplinaire Homme et Société (IRIHS), Normandie Université (NU)-Normandie Université (NU)-Université de Rouen Normandie (UNIROUEN), Normandie Université (NU), Middelheim Hospital, European Organisation for Research and Treatment of Cancer [Bruxelles] (EORTC), European Cancer Organisation [Bruxelles] (ECCO), Institut Gustave Roussy (IGR), Service d'hématologie, Centre de Lutte Contre le Cancer Henri Becquerel Normandie Rouen (CLCC Henri Becquerel), Institut d'Hématologie de Basse-Normandie (IHBN), Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Université de Caen Normandie (UNICAEN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre Mendès France - Grenoble 2 (UPMF), Université Henri Poincaré - Nancy 1 (UHP), Plateforme de génétique moléculaire des cancers d'Aquitaine, Institut Bergonié [Bordeaux], UNICANCER-UNICANCER, Erasmus Medical Centre [Rotterdam, The Netherlands], Groupe de Recherche sur les formes Injectables et les Technologies Associées - ULR 7365 (GRITA), Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille)-Université de Lille, Department of Medical Oncology, Centre Léon Bérard [Lyon], Service d'Hematologie, Hospices Civils de Lyon (HCL)-Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Department of Hematology, University Hospital St Jan, Calvados Cancer Registry, Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN), University of Groningen [Groningen], Damage and Repair in Cancer Development and Cancer Treatment (DARE), Stem Cell Aging Leukemia and Lymphoma (SALL), Université de Caen Normandie (UNICAEN), Normandie Université (NU)-Normandie Université (NU)-CHU Caen, Normandie Université (NU)-Tumorothèque de Caen Basse-Normandie (TCBN)-Tumorothèque de Caen Basse-Normandie (TCBN)-Centre Régional de Lutte contre le Cancer François Baclesse [Caen] (UNICANCER/CRLC), Normandie Université (NU)-UNICANCER-Tumorothèque de Caen Basse-Normandie (TCBN)-UNICANCER, Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hematology
Jazyk: angličtina
Rok vydání: 2012
Předmět:
Oncology
Cancer Research
endocrine system diseases
[SDV]Life Sciences [q-bio]
COMBINATION CHEMOTHERAPY
COMBINED-MODALITY
Primary Ovarian Insufficiency
DISEASE
Cohort Studies
0302 clinical medicine
INVOLVED-FIELD RADIOTHERAPY
Surveys and Questionnaires
Multicenter Studies as Topic
Survivors
MOPP
ComputingMilieux_MISCELLANEOUS
Randomized Controlled Trials as Topic
030219 obstetrics & reproductive medicine
Combination chemotherapy
Hodgkin Disease
COOPERATIVE GROUP
female genital diseases and pregnancy complications
3. Good health
Vinblastine
Premature ovarian failure
Europe
030220 oncology & carcinogenesis
Female
Cohort study
medicine.drug
Adult
medicine.medical_specialty
Adolescent
[SDV.CAN]Life Sciences [q-bio]/Cancer
Disease-Free Survival
03 medical and health sciences
Young Adult
SDG 3 - Good Health and Well-being
Translational research [ONCOL 3]
Internal medicine
medicine
Humans
VINBLASTINE
Gynecology
Dose-Response Relationship
Drug
business.industry
Cancer
ABVD
medicine.disease
Hodgkin's lymphoma
RANDOMIZED-TRIALS
Lymphoma
Fertility
CLINICAL STAGE-I
Human medicine
business
Follow-Up Studies
Zdroj: Journal of clinical oncology
Journal of Clinical Oncology, 30, 291-9
Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2012, 30 (3), pp.291-299. ⟨10.1200/JCO.2011.37.1989⟩
Journal of Clinical Oncology, 30, 3, pp. 291-9
Journal of Clinical Oncology, 30(3), 291-299. AMER SOC CLINICAL ONCOLOGY
Journal of Clinical Oncology, 2012, 30 (3), pp.291-299. ⟨10.1200/JCO.2011.37.1989⟩
Journal of Clinical Oncology, 30(3), 291-299. American Society of Clinical Oncology
ISSN: 0732-183X
1527-7755
DOI: 10.1200/JCO.2011.37.1989⟩
Popis: Purpose In this large cohort of Hodgkin's lymphoma survivors with long follow-up, we estimated the impact of treatment regimens on premature ovarian failure (POF) occurrence and motherhood, including safety of nonalkylating chemotherapy and dose-response relationships for alkylating chemotherapy and age at treatment. Patients and Methods The Life Situation Questionnaire was sent to 1,700 women treated in European Organisation for Research and Treatment of Cancer and Groupe d'Étude des Lymphomes de l'Adulte trials between 1964 and 2004. Women treated between ages 15 and 40 years and currently not using hormonal contraceptives (n = 460) were selected to assess occurrence of POF. Cumulative POF risk was estimated using the life-table method. Predictive factors were assessed by Cox regression analysis. Results Median follow-up was 16 years (range, 5 to 45 years). Cumulative risk of POF after alkylating chemotherapy was 60% (95% CI, 41% to 79%) and only 3% (95% CI, 1% to 7%) after nonalkylating chemotherapy (doxorubicin, bleomycin, vinblastine, and dacarbazine; epirubicin, bleomycin, vinblastine, and prednisone). Dose relationship between alkylating chemotherapy and POF occurrence was linear. POF risk increased by 23% per year of age at treatment. In women treated without alkylating chemotherapy at age younger than 32 years and age 32 years or older, cumulative POF risks were 3% (95% CI, 1% to 16%) and 9% (95% CI, 4% to 18%), respectively. If menstruation returned after treatment, cumulative POF risk was independent of age at treatment. Among women who ultimately developed POF, 22% had one or more children after treatment, compared with 41% of women without POF. Conclusion Nonalkylating chemotherapy carries little to no excess risk of POF. Dose-response relationships for alkylating chemotherapy and age at treatment are both linear. Timely family planning is important for women at risk of POF.
Databáze: OpenAIRE
Externí odkaz: